Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2/Neu Negative|Recurrent Inflammatory Breast Carcinoma|Stage IV Breast Cancer|Stage IV Inflammatory Breast Carcinoma
Interventions: BIOLOGICAL: Ipilimumab|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab
Sponsor: Northwestern University
Collaborators: Bristol-Myers Squibb|National Cancer Institute (NCI)